JP5951804B2 - 移植可能な医療装置及びバイオマーカーパネルデータをcrt後のlvesv低減のリスクの指標とするための方法 - Google Patents
移植可能な医療装置及びバイオマーカーパネルデータをcrt後のlvesv低減のリスクの指標とするための方法 Download PDFInfo
- Publication number
- JP5951804B2 JP5951804B2 JP2014555713A JP2014555713A JP5951804B2 JP 5951804 B2 JP5951804 B2 JP 5951804B2 JP 2014555713 A JP2014555713 A JP 2014555713A JP 2014555713 A JP2014555713 A JP 2014555713A JP 5951804 B2 JP5951804 B2 JP 5951804B2
- Authority
- JP
- Japan
- Prior art keywords
- timp
- mmp
- level
- patient
- biomarker panel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000090 biomarker Substances 0.000 title claims description 156
- 238000000034 method Methods 0.000 title claims description 96
- 230000009467 reduction Effects 0.000 title description 2
- 206010019280 Heart failures Diseases 0.000 claims description 63
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 49
- -1 sST2 Proteins 0.000 claims description 46
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims description 45
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims description 43
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 42
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 40
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 40
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 38
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 38
- 238000009125 cardiac resynchronization therapy Methods 0.000 claims description 33
- 102100024289 Metalloproteinase inhibitor 4 Human genes 0.000 claims description 26
- 108050006579 Metalloproteinase inhibitor 4 Proteins 0.000 claims description 26
- 101150106931 IFNG gene Proteins 0.000 claims description 25
- 239000012472 biological sample Substances 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 11
- 230000002861 ventricular Effects 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 9
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 208000033774 Ventricular Remodeling Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 57
- 102100032752 C-reactive protein Human genes 0.000 description 57
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 47
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 47
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 47
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 47
- 108010074328 Interferon-gamma Proteins 0.000 description 16
- 102100037850 Interferon gamma Human genes 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 12
- 230000000302 ischemic effect Effects 0.000 description 11
- 108091006146 Channels Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 8
- 238000002790 cross-validation Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 230000035488 systolic blood pressure Effects 0.000 description 8
- 238000004891 communication Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000005541 ACE inhibitor Substances 0.000 description 6
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 6
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 6
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000007477 logistic regression Methods 0.000 description 5
- 230000002797 proteolythic effect Effects 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001746 atrial effect Effects 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 229940097320 beta blocking agent Drugs 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 3
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 description 3
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 3
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002250 progressing effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102100031478 C-type natriuretic peptide Human genes 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 102400000060 Copeptin Human genes 0.000 description 2
- 101800000115 Copeptin Proteins 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108010001517 Galectin 3 Proteins 0.000 description 2
- 102100039558 Galectin-3 Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 2
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 108700025695 Suppressor Genes Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 102400001318 Adrenomedullin Human genes 0.000 description 1
- 101800004616 Adrenomedullin Proteins 0.000 description 1
- 102100029599 Advanced glycosylation end product-specific receptor Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000018746 Apelin Human genes 0.000 description 1
- 108010052412 Apelin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101800000060 C-type natriuretic peptide Proteins 0.000 description 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 description 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 description 1
- 101150093802 CXCL1 gene Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 description 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 102000011026 Fatty Acid Binding Protein 3 Human genes 0.000 description 1
- 108010062715 Fatty Acid Binding Protein 3 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 1
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 101001061840 Homo sapiens Advanced glycosylation end product-specific receptor Proteins 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- 101000585365 Homo sapiens Sulfotransferase 2A1 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102400000027 Interleukin-1 receptor type 2, soluble form Human genes 0.000 description 1
- 101800001003 Interleukin-1 receptor type 2, soluble form Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 101150073396 LTA gene Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102100027159 Membrane primary amine oxidase Human genes 0.000 description 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 108091092539 MiR-208 Proteins 0.000 description 1
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 1
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 1
- PHSRRHGYXQCRPU-AWEZNQCLSA-N N-(3-oxododecanoyl)-L-homoserine lactone Chemical compound CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O PHSRRHGYXQCRPU-AWEZNQCLSA-N 0.000 description 1
- 108010070573 NTproCNP Proteins 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000001424 Ryanodine receptors Human genes 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100029867 Sulfotransferase 2A1 Human genes 0.000 description 1
- 101150109894 TGFA gene Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 1
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 1
- 208000019269 advanced heart failure Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 108091006003 carbonylated proteins Proteins 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 238000013194 cardioversion Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007823 electrophoretic assay Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002535 isoprostanes Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091028606 miR-1 stem-loop Proteins 0.000 description 1
- 108091023685 miR-133 stem-loop Proteins 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 108091007431 miR-29 Proteins 0.000 description 1
- 108091052738 miR-486-1 stem-loop Proteins 0.000 description 1
- 108091030654 miR-486-2 stem-loop Proteins 0.000 description 1
- 108091088163 miR-760 stem-loop Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 102000034567 proadrenomedullin Human genes 0.000 description 1
- 108010012004 proadrenomedullin Proteins 0.000 description 1
- 108010034596 procollagen Type III-N-terminal peptide Proteins 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/686—Permanently implanted devices, e.g. pacemakers, other stimulators, biochips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6867—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive specially adapted to be attached or implanted in a specific body part
- A61B5/6869—Heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36557—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by chemical substances in blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Cardiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Physiology (AREA)
- Artificial Intelligence (AREA)
- Signal Processing (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
Description
好ましい実施形態において、本発明は、例えば、以下の項目を提供する。
(項目1)
移植可能な医療装置であって、
プロセッサを備え、
上記移植可能な医療装置は、少なくとも部分的に、バイオマーカーパネルのうちの1つ又は複数の定量化されたレベルに基づいて、患者を診断するように構成され、
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも2つを含む、移植可能な医療装置。
(項目2)
上記患者が独自の心不全の病因を有するか否かを判断するように構成される、項目1及び3〜11のいずれか一項に記載の移植可能な医療装置。
(項目3)
上記定量化されたレベルを、心不全を示す基準レベルと比較するように構成される、項目1、2及び4〜11のいずれか一項に記載の移植可能な医療装置。
(項目4)
上記定量化されたレベルを、心不全を示す基準レベルと比較し、心エコー図データを解析するように構成される、項目1〜3及び5〜11のいずれか一項に記載の移植可能な医療装置。
(項目5)
定量化されたレベルを基準正常レベルと比較するように構成される、項目1〜4及び6〜11のいずれか一項に記載の移植可能な医療装置。
(項目6)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも3つを含む、項目1〜5及び7〜11のいずれか一項に記載の移植可能な医療装置。
(項目7)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも4つを含む、項目1〜6及び8〜11のいずれか一項に記載の移植可能な医療装置。
(項目8)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも5つを含む、項目1〜7及び9〜11のいずれか一項に記載の移植可能な医療装置。
(項目9)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも6つを含む、項目1〜8、10、及び11のいずれか一項に記載の移植可能な医療装置。
(項目10)
上記バイオマーカーパネルは、少なくともCRP、sTNFR−II、及びBNPを含む、項目1〜9及び11のいずれか一項に記載の移植可能な医療装置。
(項目11)
上記バイオマーカーパネルは、少なくともCRP、sST2、TIMP−1、及びTIMP−2を含む、項目1〜10のいずれか一項に記載の移植可能な医療装置。
(項目12)
患者をスクリーニングする方法であって、
患者の生物学的サンプルのバイオマーカーパネルのうちの1つ又は複数のレベルを定量化することと、
上記定量化されたレベルを解析することと、
を含み、
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも2つを含む、方法。
(項目13)
上記定量化されたレベルを解析することは、上記患者が、心不全の代償不全を受けるリスクを有するか否かを判断することを含む、項目12及び14〜28のいずれか一項に記載の方法。
(項目14)
上記定量化されたレベルを解析することは、上記患者が、心不全の臨床症状が急速に低下するリスクを有するか否かを判断することを含む、12、13及び15〜28のいずれか一項に記載の方法。
(項目15)
上記定量化されたレベルを解析することは、上記患者が有害な心室リモデリングリスクを有するか否かを判断することを含む、項目12〜14及び16〜28のいずれか一項に記載の方法。
(項目16)
上記定量化されたレベルを解析することは、上記患者が不整脈リスクを有するか否かを判断することを含む、項目12〜15及び17〜28のいずれか一項に記載の方法。
(項目17)
上記定量化されたレベルを解析することは、定量化されたレベルを基準正常レベルと比較することを含む、項目12〜16及び18〜28のいずれか一項に記載の方法。
(項目18)
上記定量化されたレベルを解析することは、上記定量化されたレベルを使用して、上記患者を、心不全進行リスクに関連する1組のカテゴリの1つに分けることを含む、項目12〜17及び19〜28のいずれか一項に記載の方法。
(項目19)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも3つを含む、項目12〜18及び20〜28のいずれか一項に記載の方法。
(項目20)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも4つを含む、項目12〜19及び21〜28のいずれか一項に記載の方法。
(項目21)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも5つを含む、項目12〜20及び22〜28のいずれか一項に記載の方法。
(項目22)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも6つを含む、項目12〜21及び23〜28のいずれか一項に記載の方法。
(項目23)
上記バイオマーカーパネルは、少なくともCRP、sTNFR−II、及びBNPを含む、項目12〜22及び24〜28のいずれか一項に記載の方法。
(項目24)
上記バイオマーカーパネルは、少なくともCRP、sST2、TIMP−1、及びTIMP−2を含む、項目12〜23及び25〜28のいずれか一項に記載の方法。
(項目25)
上記生物学的サンプルはプラズマを含む、項目12〜24及び26〜28のいずれか一項に記載の方法。
(項目26)
レベルを定量化することは、生体外で行われる、項目12〜25、27、及び28のいずれか一項に記載の方法。
(項目27)
レベルを定量化することは、生体内で行われる、項目12〜26、及び28のいずれか一項に記載の方法。
(項目28)
患者の生物学的サンプルを採取するステップを更に含む、項目12〜27のいずれか一項に記載の方法。
(項目29)
患者を診断する方法であって、
患者の生物学的サンプルのバイオマーカーパネルのうちの1つ又は複数のレベルを定量化することと、
少なくとも部分的に上記定量化されたレベルに基づいて上記患者を診断することと、
を含み、
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも2つを含む、方法。
(項目30)
上記患者を診断することは、少なくとも部分的に、時間の経過に伴う上記定量化されたレベルの変化に基づく、項目29及び31〜46のいずれか一項に記載の方法。
(項目31)
時間の経過に伴う上記定量化されたレベルの変化の傾向を識別することを更に含む、項目29、30及び32〜46のいずれか一項に記載の方法。
(項目32)
上記患者を診断することは、上記患者が独自の心不全の病因を有するか否かを判断することを含む、項目29〜31及び33〜46のいずれか一項に記載の方法。
(項目33)
上記患者を診断することは、上記定量化されたレベルを、心不全を示す基準レベルと比較することを含む、項目29〜32及び34〜46のいずれか一項に記載の方法。
(項目34)
上記患者を診断することは、心エコー図データの解析と併せて、上記定量化されたレベルを、心不全を示す基準レベルと比較することを含む、項目29〜33及び35〜46のいずれか一項に記載の方法。
(項目35)
上記患者を診断することは、定量化されたレベルを基準正常レベルと比較することを含む、項目29〜34及び36〜46のいずれか一項に記載の方法。
(項目36)
レベルを定量化するステップの前に、心不全の症状を示す患者を選択することを更に含む、項目29〜35及び37〜46のいずれか一項に記載の方法。
(項目37)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも3つを含む、項目29〜36及び38〜46のいずれか一項に記載の方法。
(項目38)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも4つを含む、項目29〜37及び39〜46のいずれか一項に記載の方法。
(項目39)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも5つを含む、項目29〜38及び40〜46のいずれか一項に記載の方法。
(項目40)
上記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも6つを含む、項目29〜39及び41〜46のいずれか一項に記載の方法。
(項目41)
上記バイオマーカーパネルは、少なくともCRP、sTNFR−II、及びBNPを含む、項目29〜40及び42〜46のいずれか一項に記載の方法。
(項目42)
上記バイオマーカーパネルは、少なくともCRP、sST2、TIMP−1、及びTIMP−2を含む、項目29〜41及び43〜46のいずれか一項に記載の方法。
(項目43)
上記生物学的サンプルはプラズマを含む、項目29〜42及び44〜46のいずれか一項に記載の方法。
(項目44)
レベルを定量化することは、生体外で行われる、項目29〜43、45、及び46のいずれか一項に記載の方法。
(項目45)
レベルを定量化することは、生体内で行われる、項目29〜44及び46のいずれか一項に記載の方法。
(項目46)
患者の生物学的サンプルを採取するステップを更に含む、項目29〜45のいずれか一項に記載の方法。
トライアルに登録した心不全を有する患者(n=764)から、ベースライン(CRT評価中であるが、CRT移植前)で、CRTが配置されてから3か月後、及び6か月後に前向き調査でプラズマを収集した。Ellenbogenら、Primary results from the SmartDelay determined AV optimization:a comparison to other AV delay methods used in cardiac resynchronization therapy(SMART−AV)trial.Circulation 2010;122:2660−2668参照。トライアルは、機能的反応として、CRT後6か月での15mlのLV収縮末期容量の低減という、予め指定された評価項目を確立し、この定義をこのバイオマーカープロファイリング研究で利用した。トライアルの初期目標は、CRT房室(A−V)遅延の3つの異なるモードを比較することであり、続くランダム化は、主要評価項目と比較的等しいことを示し、したがって、これらの患者を本解析に向けてプールした。
Claims (18)
- 移植可能な医療装置であって、
プロセッサを備え、
前記移植可能な医療装置は、少なくとも部分的に、バイオマーカーパネルの定量化されたレベルに基づいて、患者の予測される心臓再同期療法(CRT)反応を診断するように構成され、前記CRT反応は、CRT後の左心室収縮末期容量(LVESV)の変化であり、
前記バイオマーカーパネルは、少なくともCRP、sTNFR−II、及びBNPを含むか、または少なくともCRP、sST2、TIMP−1、及びTIMP−2を含む、移植可能な医療装置。 - 前記患者が独自の心不全の病因を有するか否かを判断するように構成される、請求項1に記載の移植可能な医療装置。
- 前記定量化されたレベルを、心不全を示す基準レベルと比較するように構成される、請求項1及び2のいずれか一項に記載の移植可能な医療装置。
- 前記定量化されたレベルを、心不全を示す基準レベルと比較し、心エコー図データを解析するように構成される、請求項1〜3のいずれか一項に記載の移植可能な医療装置。
- 定量化されたレベルを基準正常レベルと比較するように構成される、請求項1〜4のいずれか一項に記載の移植可能な医療装置。
- 前記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも5つを含む、請求項1〜5のいずれか一項に記載の移植可能な医療装置。
- 前記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも6つを含む、請求項1〜6のいずれか一項に記載の移植可能な医療装置。
- バイオマーカーパネルを、患者が心臓再同期療法(CRT)後の左心室収縮末期容量(LVESV)の低減のリスクを有するか否かの指標とするための方法であって、前記方法は、
前記患者の生物学的サンプルの前記バイオマーカーパネルのレベルを定量化することと、
前記定量化されたレベルを解析することと、
を含み、
前記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも2つを含む、方法。 - 前記バイオマーカーパネルのレベルを、前記患者が心不全の代償不全を受けるリスクを有するか否かの指標とする、請求項8に記載の方法。
- 前記バイオマーカーパネルのレベルを、前記患者が心不全の臨床症状が急速に低下するリスクを有するか否かの指標とする、8〜9のいずれか一項に記載の方法。
- 前記バイオマーカーパネルのレベルを、前記患者が有害な心室リモデリングリスクを有するか否かの指標とする、請求項8〜10のいずれか一項に記載の方法。
- 前記バイオマーカーパネルのレベルを、前記患者が不整脈リスクを有するか否かの指標とする、請求項8〜11のいずれか一項に記載の方法。
- 前記定量化されたレベルを解析することは、定量化されたレベルを基準正常レベルと比較することを含む、請求項8〜12のいずれか一項に記載の方法。
- 前記定量化されたレベルを解析することは、前記定量化されたレベルを使用して、前記患者を、心不全進行リスクに関連する1組のカテゴリの1つに分けることを含む、請求項8〜13のいずれか一項に記載の方法。
- 前記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも4つを含む、請求項8〜14のいずれか一項に記載の方法。
- 前記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも5つを含む、請求項8〜15のいずれか一項に記載の方法。
- 前記バイオマーカーパネルは、CRP、SGP−130、sIL−2R、sTNFR−II、IFNg、BNP、sST2、MMP−2、MMP−9、TIMP−1、TIMP−2、TIMP−4からなる群から選択される少なくとも6つを含む、請求項8〜16のいずれか一項に記載の方法。
- 前記生物学的サンプルはプラズマを含む、請求項8〜17のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261593046P | 2012-01-31 | 2012-01-31 | |
US61/593,046 | 2012-01-31 | ||
PCT/US2013/024189 WO2013116547A1 (en) | 2012-01-31 | 2013-01-31 | Implantable device and methods for diagnosing heart failure using biomarker panel data |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015510417A JP2015510417A (ja) | 2015-04-09 |
JP5951804B2 true JP5951804B2 (ja) | 2016-07-13 |
Family
ID=47710357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014555713A Active JP5951804B2 (ja) | 2012-01-31 | 2013-01-31 | 移植可能な医療装置及びバイオマーカーパネルデータをcrt後のlvesv低減のリスクの指標とするための方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130196870A1 (ja) |
EP (1) | EP2809392B1 (ja) |
JP (1) | JP5951804B2 (ja) |
CN (1) | CN104136072B (ja) |
WO (1) | WO2013116547A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8602996B2 (en) | 2010-06-01 | 2013-12-10 | Cardiac Pacemakers, Inc. | Integrating device-based sensors and bedside biomarker assays to detect worsening heart failure |
JP2015510416A (ja) | 2012-01-31 | 2015-04-09 | カーディアック ペースメイカーズ, インコーポレイテッド | バイオマーカーパネルデータを使用して、心臓再同期装置/治療を制御するシステム及び方法 |
US20200057075A1 (en) * | 2017-02-20 | 2020-02-20 | The Regents Of The University Of California | Serologic assay for silent brain ischemia |
CN112292178A (zh) * | 2018-06-14 | 2021-01-29 | 美敦力公司 | 用于心脏重塑的心脏起搏治疗的递送 |
WO2021141950A1 (en) * | 2020-01-06 | 2021-07-15 | W. L. Gore & Associates, Inc. | Conditioning algorithms for biomarker sensor measurements |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4562841A (en) | 1982-08-05 | 1986-01-07 | Cardiac Pacemakers, Inc. | Programmable multi-mode cardiac pacemaker |
DE60235416D1 (de) * | 2001-05-04 | 2010-04-01 | Biosite Inc | Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen |
US7632234B2 (en) * | 2003-08-29 | 2009-12-15 | Medtronic, Inc. | Implantable biosensor devices for monitoring cardiac marker molecules |
US20050234336A1 (en) * | 2004-03-26 | 2005-10-20 | Beckman Andrew T | Apparatus and method for marking tissue |
CA2511269A1 (en) * | 2004-07-07 | 2006-01-07 | F. Hoffmann-La Roche Ag | Multimarker panel based on p1gf for diabetes type 1 and 2 |
CA2604563C (en) * | 2005-04-15 | 2020-07-28 | Surgisense Corporation | Surgical instruments with sensors for detecting tissue properties, and systems using such instruments |
US7907997B2 (en) * | 2005-05-11 | 2011-03-15 | Cardiac Pacemakers, Inc. | Enhancements to the detection of pulmonary edema when using transthoracic impedance |
US20070141627A1 (en) * | 2005-10-19 | 2007-06-21 | Behrens Timothy W | Systemic Lupus Erythematosus |
US20080044843A1 (en) * | 2005-12-21 | 2008-02-21 | Lorah Perlee | Biomarkers for chronic obstructive pulmonary disease |
US8126554B2 (en) | 2006-05-17 | 2012-02-28 | Cardiac Pacemakers, Inc. | Implantable medical device with chemical sensor and related methods |
US20100015643A1 (en) * | 2006-05-19 | 2010-01-21 | Chuwa Tei | Method of quantitative determination of antigen protein and quantitative determination kit therefor |
JP2009544013A (ja) * | 2006-07-11 | 2009-12-10 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | プロテアーゼおよびプロテアーゼ阻害因子のプロファイリングによる心筋梗塞後の心不全の予測 |
US8506499B2 (en) * | 2007-01-04 | 2013-08-13 | Musc Foundation For Research Development | Predicting atrial fibrillation recurrence by protease and protease inhibitor profiling |
US20100233727A1 (en) * | 2007-09-11 | 2010-09-16 | Dudley Jr Samuel C | Marker for arrhythmia risk |
WO2009100907A1 (en) * | 2008-02-14 | 2009-08-20 | Dianeering Diagnostics Engineering And Research Gmbh | Means and methods for assessing the risk of patients presenting to emergency departments based on very low concentrations of troponin i or t or using a combination of markers |
WO2010012616A1 (en) * | 2008-07-30 | 2010-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blood glutathione as a biomarker for screening asymptomatic patients at risk for heart failure |
HU0900534D0 (en) * | 2009-08-29 | 2009-10-28 | Semmelweis Egyetem | Method and kit for improvement of prognosing of heart failure |
US8602996B2 (en) * | 2010-06-01 | 2013-12-10 | Cardiac Pacemakers, Inc. | Integrating device-based sensors and bedside biomarker assays to detect worsening heart failure |
AU2013262515B2 (en) * | 2012-05-18 | 2018-03-15 | Cardiac Pacemakers, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
-
2013
- 2013-01-31 CN CN201380007515.8A patent/CN104136072B/zh active Active
- 2013-01-31 EP EP13703982.2A patent/EP2809392B1/en active Active
- 2013-01-31 US US13/756,135 patent/US20130196870A1/en not_active Abandoned
- 2013-01-31 WO PCT/US2013/024189 patent/WO2013116547A1/en active Application Filing
- 2013-01-31 JP JP2014555713A patent/JP5951804B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN104136072A (zh) | 2014-11-05 |
US20130196870A1 (en) | 2013-08-01 |
JP2015510417A (ja) | 2015-04-09 |
CN104136072B (zh) | 2016-08-24 |
EP2809392A1 (en) | 2014-12-10 |
EP2809392B1 (en) | 2016-09-14 |
WO2013116547A1 (en) | 2013-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11340236B2 (en) | Methods for treating or predicting risk of a ventricular tachyarrhythmia event | |
JP6902083B2 (ja) | マルチマーカーリスク層別化 | |
JP5951804B2 (ja) | 移植可能な医療装置及びバイオマーカーパネルデータをcrt後のlvesv低減のリスクの指標とするための方法 | |
US10502747B2 (en) | Systems and methods using biomarker panel data | |
Stanciu et al. | NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure | |
CN111263887B (zh) | 用于评价心房颤动(af)的脂肪酸结合蛋白3 | |
Scolari et al. | Clonal haematopoiesis is associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy | |
Edgar et al. | 56 Novel heart failure biomarker CLEC3B is associated with cardiac fibrosis, and impacts cardiac fibroblast cell function | |
Phelan et al. | Modest Elevation in BNP in Asymptomatic Hypertensive Patients Reflects Sub-Clinical | |
Felker et al. | Biologic markers in acute heart failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20150420 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150427 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150703 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20150708 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151118 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160510 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5951804 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |